醛固酮拮抗剂在心力衰竭治疗中的应用  

Application of aldosterone antagonists in the treatment of heart failure

作　　者：高修仁[1] 黄至斌[1] 

机构地区：[1]中山大学附属第一医院心内科,广州510080

出　　处：《上海医药》2013年第17期15-19,共5页Shanghai Medical & Pharmaceutical Journal

摘　　要：人们对醛固酮致病作用的认识已有50多年的历史,但相关指南推荐使用醛固酮拮抗剂治疗纽约心脏协会心功能分级Ⅲ～Ⅳ级、左心室射血分数≤35%的重度心力衰竭患者却仅有10年的时间。2012年,欧洲心脏病学学会发表的更新指南又将醛固酮拮抗剂治疗心力衰竭的适用人群扩展到纽约心脏协会心功能分级Ⅱ级患者。本文概要介绍醛固酮拮抗剂的作用机制、循证医学证据和注意事项等。More than 50 years ago, scientist first observed the relationship between heart failure and aldosterone. However aldosterone antagonists were not guideline-recommended as a therapy for patients with moderate to severe heart failure till 10 years ago. In 2012 ESC guideline for aldosterone antagonists in the treatment of systolic heart failure extended to patients with mild heart failure. This review introduces the main mechanism, evidence-based medicine, clinical therapy and announcements for aldosterone antagonists in the treatment of systolic heart failure.

关 键 词：醛固酮拮抗剂 螺内酯 伊普利酮 心力衰竭 

分 类 号：R541.6[医药卫生—心血管疾病]